Group
Anti-RANKL mAb
The data below refer to patients treated with Anti-RANKL mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Denosumab
No data